Manage Tickers

Has my stock been accused of fraud?Join over 160k users who know.

Ticker Price Change($) Change(%) Shares Volume Prev Close Open Gain($) Gain(%)
Ticker Status Jurisdiction Filing Date CP Start CP End CP Loss Deadline
Ticker Case Name Status CP Start CP End Deadline Settlement Amt
Ticker Name Date Analyst Firm Up/Down Target ($) Rating Change Rating Current
Analyst Rating Guide

News

Back

Evogene Q4 2024 GAAP EPS $0.06 May Not Be Comparable To $(0.72) Estimate, Sales $1.61M Miss $3.63M Estimate

Author: Benzinga Newsdesk | March 06, 2025 07:17am
Evogene (NASDAQ:EVGN) reported quarterly earnings of $0.06 per share which beat the analyst consensus estimate of $(0.72) by 108.33 percent. This is a 104.62 percent increase over losses of $(1.30) per share from the same period last year. The company reported quarterly sales of $1.61 million which missed the analyst consensus estimate of $3.63 million by 55.56 percent. This is a 178.72 percent increase over sales of $578.00 thousand the same period last year.

Posted In: EVGN


CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION

CORE Finalist